Table 5:
Distribution of NOACs.
NOAC
Total (%)
no SEC
SEC
Dabigatran
47 (18.4%)
42 (89.4%)
5 (10.4%)
Apixaban
56 (22%)
54 (96.4%)
2 (3.6%)
Rivaroxaban
152 (59.6%)
140 (92.1%)
12 (7.1%)